Leinco Technologies

Recombinant Human EMAP-II

Product Code:
 
LEI-E142
Product Group:
 
Recombinant Proteins
Host Type:
 
Human
Regulatory Status:
 
RUO
Storage:
 
The lyophilized protein should be stored desiccated at -20°C. The reconstituted protein can be stored for at least one week at 4°C. For long-term storage of the reconstituted protein aliquot into working volumes and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-E142-20ug20 ug£532.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Long Description:
Endothelial monocyte activating polypeptide II (EMAP II) is a pro-inflammatory cytokine with anti-angiogenic properties. This protein was discovered in the supernatant of Meth-A fibrosarcoma cells and was shown to enhance the induction of the procoagulant Tissue Factor (TF) on endothelial cells. Besides up-regulation of TF mRNA, EMAP II increases cellular receptors for TNF on endothelial cells, which is likely to enhance the predisposition of tumors to undergo thrombosis and hemorrhagic necrosis, once challenged with TNF.1 EMAP II functions as a potent inhibitor of primary and metastatic tumor growth, has strong inhibitory effects on endothelial cells and can reduce intratumoral expression of the angiogenesis inducer vascular endothelial growth factor (VEGF). 2 It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils.
Purity:
>98% by SDS Page and HPLC
Target:
Endothelial Monocyte Activating Polypeptide-II

References

1. Ten Hagen TL. et al. (2004) Anticancer Res. 24: 2243 2. Schwarz RE. et al. (2009) Lab Invest. 89: 38